ProfileGDS5678 / 1421853_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 86% 85% 89% 87% 86% 88% 87% 86% 85% 86% 87% 90% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4358886
GSM967853U87-EV human glioblastoma xenograft - Control 26.6008386
GSM967854U87-EV human glioblastoma xenograft - Control 36.3585
GSM967855U87-EV human glioblastoma xenograft - Control 47.2781689
GSM967856U87-EV human glioblastoma xenograft - Control 56.7843887
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3449686
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.586588
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6042587
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4445986
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.4770285
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4464286
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.7602687
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.1692290
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.6455487